Premium
Effects of oestrogen replacement therapy on serum C‐reactive protein levels in hysterectomised women
Author(s) -
Kiran Hakan,
Kiran Gurkan,
Ekerbicer Hasan C.,
Guven Alanur M.,
Kilinc Metin
Publication year - 2004
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.2004.00183.x
Subject(s) - medicine , c reactive protein , nasal administration , postmenopausal women , inflammation , hormone replacement therapy (female to male) , prospective cohort study , estrogen , endocrinology , gastroenterology , pharmacology , testosterone (patch)
Background: It has been hypothesised that oral oestrogen replacement therapy may increase levels of C‐reactive protein (CRP), a marker of inflammation associated with increased risk of future cardiovascular events. However, it is possible that intranasal oestrogen replacement therapy have different effects on serum CRP levels. Aim: To investigate the effect of postmenopausal intranasal oestrogen replacement therapy on serum levels of CRP. A prospective comparative study was carried out. Methods: Twenty‐nine healthy hysterectomised, postmenopausal women received 300 µg/day of intranasal 17β‐oestradiol (E2). The serum levels of CRP after 3 and 6 months after starting treatment were compared with baseline values. Results: There were no significant changes in the values of CRP after 3 and 6 months of treatment ( P = 0.305, P = 0.149, respectively). Conclusions: The data from the present study suggest that intranasal administration of E2 does not affect CRP levels, possibly by avoiding a hepatic first‐pass effect. The possible cardiovascular protective role of intranasal oestrogen might be related to its effect of not increasing CRP levels.